Mirtazapine: Supply issue

Supply issue Active

Supply of mirtazapine is running low. We are listing another brand to ensure continued supply.

Supply issue with 30 mg and 45 mg tablets

The supplier of mirtazapine, Apotex, have advised that stocks of their 30 mg tablets and 45 mg tablets are likely to run out during August and September 2021.

Alternative product: Noumed 

From 1 August 2021, we are listing another brand of mirtazapine ("Noumed") to make sure people can continue to get the medicine they need. This brand will be supplied by Noumed.

This brand of mirtazapine does not currently have Medsafe approval so would need to be supplied under section 29 of the Medicines Act.

We apologise for any inconvenience this may cause to people taking mirtazapine, pharmacists, and prescribers.

Prescribing and supplying an unapproved medicine 

Section 29 of the Medicines Act allows for medicines that are not Medsafe approved to be prescribed and supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – eg a doctor. 

We know supplying a medicine under section 29 is not ideal. In this case, however, the alternative would be for people to have no mirtazapine. 

We apologise for any inconvenience this causes. 

Prescriber and pharmacist requirements for section 29 medicines – Medsafe website(external link)

What patients need to know about section 29 medicines – Health Navigator website(external link)

Who to contact

If you take mirtazapine, you are best to talk to your pharmacist or the person who prescribes your mirtazapine. They know your clinical circumstances and are in the best place to advise you.

If you have questions about the funding of mirtazapine, email enquiry@pharmac.govt.nz

Pharmac's response to Apotex's departure